Euroopa Liit - eesti - EMA (European Medicines Agency)

pfizer europe ma eeig - tofacitinib - artriit, reumatoidartriit - immunosupressandid - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 ja 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.

Euroopa Liit - eesti - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - transplantaadi tagasilükkamine - immunosupressandid - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Euroopa Liit - eesti - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - totsilizumab - arthritis, rheumatoid; cytokine release syndrome; arthritis, juvenile rheumatoid; covid-19 virus infection; giant cell arteritis - immunosupressandid - tyenne, in combination with methotrexate (mtx), is indicated for- the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx. - the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists. in these patients, tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tocilizumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. tyenne is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. tyenne can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx. tyenne in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tyenne is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older. tyenne is indicated for the treatment of giant cell arteritis (gca) in adult patients.

Euroopa Liit - eesti - EMA (European Medicines Agency)

nordic group b.v. - metotreksaadi - arthritis, psoriatic; psoriasis; arthritis, juvenile rheumatoid; arthritis, rheumatoid - antineoplastilised ained - nordimet is indicated for the treatment of:active rheumatoid arthritis in adult patients,polyarthritic forms of severe, active juvenile idiopathic arthritis (jia), when the response to nonsteroidal anti-inflammatory drugs (nsaids) has been inadequate,moderate to severe plaque psoriasis in adults who are candidates for systemic therapy, and severe psoriatic arthritis in adult patients, induction of remission in moderate steroid-dependent crohn's disease in adult patients, in combination with corticosteroids and for maintenance of remission, as monotherapy, in patients who have responded to methotrexate.

Euroopa Liit - eesti - EMA (European Medicines Agency)

therakind (europe) limited - metotreksaadi - arthritis, psoriatic; precursor cell lymphoblastic leukemia-lymphoma; psoriasis; arthritis, rheumatoid; arthritis - antineoplastilised ained - selles rheumatological ja nahahaiguste diseasesactive reumatoidartriidiga täiskasvanud patsientidel. polyarthritic vormid, aktiivne, tõsine juveniilne idiopaatiline artriit (jia) noorukitel ja lastel vanuses 3 aastat ja rohkem, kui vastuseks mitte-steroidsete põletikuvastaste ravimite (mspva) on olnud ebapiisav. tõsiseid, ravi-tulekindlad -, blokeerimis-psoriaas, mis ei allu piisavalt muud liiki ravile, nt valgusravi, psoralen ja ultraviolett kiirguse (puva) ravi ja retinoidide, ja raske psoriaatiline artriit täiskasvanud patsientidel. selles oncologymaintenance ravi ägeda lümfoblastilise leukeemia (all) täiskasvanutel, noorukitel ja lastel vanuses 3 aastat ja rohkem.

Eesti - eesti - Ravimiamet

first pharma oÜ - asatiopriin - õhukese polümeerikattega tablett - 50mg 100tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - rituksimab - lymphoma, non-hodgkin; arthritis, rheumatoid; wegener granulomatosis; leukemia, lymphocytic, chronic, b-cell; microscopic polyangiitis - antineoplastilised ained - truxima on näidatud täiskasvanute jaoks järgmisi andmeid:mitte-hodgkini lümfoom (nhl)truxima on näidustatud raviks eelnevalt ravimata patsientidel iii etapp iv follikulaarne lümfoom kombinatsioonis keemiaraviga. truxima säilitusravi, on näidustatud ravi follikulaarne lümfoom patsientide reageerimine induktsiooni teraapia. truxima monotherapy on näidustatud patsientidele, kellel iii etapp iv follikulaarne lümfoom, kes on kemo vastupidavad või on oma teine või järgmine hakkavad pärast keemiaravi. truxima on näidustatud patsientide raviks cd20 positiivne hajus suur b-rakkude mitte hodgkini lümfoom koos karbonaad (tsüklofosfamiid, doxorubicin, vincristine, prednisoloon) keemiaravi. krooniline lümfoidne leukeemia (cll)truxima kombinatsioonis keemiaraviga on näidustatud patsientide raviks eelnevalt ravimata ja taastekkinud/tulekindlad cll. on kättesaadavad ainult piiratud andmed selliste ravimite efektiivsuse ja ohutuse kohta, mida varem raviti monoklonaalsete antikehadega, sh truxima'ga või eelneva truxima ja kemoteraapiat põdevate patsientidega. reumatoidartriidi arthritistruxima koos metotreksaadi on näidustatud ravi täiskasvanud patsientidel, kellel on raske aktiivne reumatoidartriit, kes on ebaadekvaatne reaktsioon või talu teisi haigust moduleeriva anti reumaatilised ravimeid (dmard), sh ühte või enamat tuumori nekroosi faktori (tnf) inhibiitorite ravi. truxima on näidanud, et vähendada määra progressioon ühise kahju, mida mõõdetakse x-ray ja parandab füüsilist funktsiooni, kui antud koos metotreksaadi. granulomatosis koos polyangiitis ja mikroskoopilised polyangiitistruxima, koos glucocorticoids, on näidustatud ravi täiskasvanud patsientidel, kellel on raske, aktiivse granulomatosis koos polyangiitis (wegener ' s) (gpa) ja mikroskoopilised polyangiitis (mpa). pemphigus vulgaristruxima on näidustatud ravi patsientidel, kellel on mõõdukas kuni raske pemphigus vulgaris (pv).

Euroopa Liit - eesti - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - rituksimab - lymphoma, non-hodgkin; microscopic polyangiitis; wegener granulomatosis - antineoplastilised ained - ritemvia on näidatud täiskasvanute jaoks järgmisi andmeid:mitte-hodgkini lümfoom (nhl) ritemvia on näidustatud raviks eelnevalt ravimata patsientidel etapp, iii, iv follikulaarne lümfoom kombinatsioonis keemiaraviga. ritemvia säilitusravi, on näidustatud ravi follikulaarne lümfoom patsientide reageerimine induktsiooni teraapia. ritemvia monotherapy on näidustatud patsientidele, kellel etapp, iii, iv follikulaarne lümfoom, kes on kemo vastupidavad või on oma teine või järgmine hakkavad pärast keemiaravi. ritemvia on näidustatud patsientide raviks cd20 positiivne hajus suur b-rakkude mitte hodgkini lümfoom koos karbonaad (tsüklofosfamiid, doxorubicin, vincristine, prednisoloon) keemiaravi. granulomatosis koos polyangiitis ja mikroskoopilised polyangiitis. ritemvia, koos glucocorticoids, on näidustatud remissiooni induktsioon täiskasvanud patsientidel, kellel on raske, aktiivse granulomatosis koos polyangiitis (wegener) (gpa) ja mikroskoopilised polyangiitis (mpa).

Euroopa Liit - eesti - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - rituksimab - lymphoma, non-hodgkin; microscopic polyangiitis; leukemia, lymphocytic, chronic, b-cell; wegener granulomatosis - antineoplastilised ained - rituzena on näidatud täiskasvanute jaoks järgmisi andmeid:mitte-hodgkini lümfoom (nhl)rituzena on näidustatud raviks eelnevalt ravimata patsientidel iii etapp iv follikulaarne lümfoom kombinatsioonis keemiaraviga. rituzena monotherapy on näidustatud patsientidele, kellel iii etapp iv follikulaarne lümfoom, kes on kemo vastupidavad või on oma teine või järgmine hakkavad pärast keemiaravi. rituzena on näidustatud patsientide raviks cd20 positiivne hajus suur b-rakkude mitte hodgkini lümfoom koos karbonaad (tsüklofosfamiid, doxorubicin, vincristine, prednisoloon) keemiaravi. krooniline lümfoidne leukeemia (cll)rituzena kombinatsioonis keemiaraviga on näidustatud patsientide raviks eelnevalt ravimata ja taastekkinud/tulekindlad cll. ainult piiratud andmed on saadaval efektiivsust ja ohutust patsientidel, eelnevalt ravitud monoklonaalsete antikehadega (sealhulgas rituzenaor patsientidel, tulekindlad, et eelmise rituzena pluss kemoteraapiat. granulomatosis koos polyangiitis ja mikroskoopilised polyangiitisrituzena, koos glucocorticoids, on näidustatud remissiooni induktsioon täiskasvanud patsientidel, kellel on raske, aktiivse granulomatosis koos polyangiitis (wegener) (gpa) ja mikroskoopilised polyangiitis (mpa).

Euroopa Liit - eesti - EMA (European Medicines Agency)

sandoz gmbh - rituksimab - lymphoma, non-hodgkin; arthritis, rheumatoid; microscopic polyangiitis; wegener granulomatosis - antineoplastilised ained - riximyo is indicated in adults for the following indications:non-hodgkin’s lymphoma (nhl)riximyo is indicated for the treatment of previously untreated adult patients with stage iii-iv follicular lymphoma in combination with chemotherapy. riximyo maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy. riximyo monotherapy is indicated for treatment of adult patients with stage iii-iv follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy. riximyo is indicated for the treatment of adult patients with cd20 positive diffuse large b cell non-hodgkin’s lymphoma in combination with chop (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. riximyo in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage cd20 positive diffuse large b-cell lymphoma (dlbcl), burkitt lymphoma (bl)/burkitt leukaemia (mature b-cell acute leukaemia) (bal) or burkitt-like lymphoma (bll). chronic lymphocytic leukaemia (cll)riximyo in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. ainult piiratud andmed on saadaval efektiivsust ja ohutust patsientidel, eelnevalt ravitud monoklonaalsete antikehadega (sealhulgas rituksimabi või patsientidel, tulekindlad, et eelmise rituksimabi pluss kemoteraapiat. vt lõik 5. 1 lisateavet. rheumatoid arthritisriximyo in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (dmard) including one or more tumour necrosis factor (tnf) inhibitor therapies. rituksimabi on näidanud, et vähendada määra progressioon ühise kahju, mida mõõdetakse x-ray ja parandab füüsilist funktsiooni, kui antud koos metotreksaadi. granulomatosis with polyangiitis and microscopic polyangiitisriximyo, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (wegener’s) (gpa) and microscopic polyangiitis (mpa). riximyo, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active gpa (wegener’s) and mpa. pemphigus vulgarisriximyo is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (pv).